Cambridge, MA -- Conselium has announced the completion of an executive search on behalf of Biogen Idec Inc. Biogen has named Mr. Troy Morgan its new Director of Compliance, effective October 5, 2009.
Conselium, an executive search firm, has just completed a search for a Director of Compliance in Cambridge, MA on behalf of Biogen Idec Inc. Mr. Troy Morgan will begin his role of Director of Compliance October 5, 2009.
Mr. Morgan will be responsible for:
- Development and execution of R&D policies, SOPs, guidance, etc. based on prioritized needs in coordination with Global Compliance and other functions
- Acting as the point of contact for R&D on all compliance-related issues
- Identifying priority areas for the development and implementation of an international, risk-based compliance monitoring and auditing program R&D
- Leading the development, communication and implementation of all R&D policies and SOPs
Mr. Morgan was previously Global Ethics & Compliance Counsel for GE Healthcare. Mr. Morgan’s previous professional positions include VP of Legal Programs at Consolidated Legal Concepts, and Litigation Partner at Holloway & Elliott, LLC. Mr. Morgan obtained his Jurist Doctor from Faulkner University’s Jones School of Law.
Biogen Idec of Cambridge, MA has $4.2BB in revenue. The biotech giant, formed from the merger of IDEC Pharmaceuticals and Biogen, is focused on developing treatments in the areas of oncology, immunology, and neurology. Its product roster includes best-selling Avonex, the most popular drug for the treatment of relapsing multiple sclerosis; Rituxan, a monoclonal antibody developed with Genentech that treats B-cell non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis; multiple sclerosis and Crohn's disease drug Tysabri; and Fumaderm, a psoriasis drug marketed in Germany. Biogen Idec serves customers in more than 90 countries.
